Hims & Hers Well being (HIMS) inventory fell as a lot as 5% early Tuesday after the corporate reported income late Monday that fell shy of Wall Avenue forecasts whereas sustaining its full-year forecast.
The telehealth firm posted income of $544.8 million within the second quarter, marking a 73% improve yr over yr however lacking analyst estimates for $552 million, based on Bloomberg information. Hims & Hers maintained its full-year income steerage of $2.3 billion to $2.4 billion.
Earnings per share topped forecasts, coming in at $0.17 in opposition to expectations for $0.15.
The inventory had dropped as a lot as 11% in premarket commerce.
Learn extra about right now’s market motion.
The corporate’s slide comes after drugmaker Novo Nordisk (NVO) ended a short-lived partnership between the 2 firms in June that noticed Novo Nordisk permit Hims & Hers entry to its viral weight-loss drug Wegovy.
Novo Nordisk alleged within the announcement that Hims & Hers “has failed to stick to the regulation which prohibits mass gross sales of compounded medicine underneath the false guise of ‘personalization’ and are disseminating misleading advertising and marketing that put affected person security in danger.”
Novo Nordisk inventory fell greater than 21% final month after the drugmaker introduced it was slashing revenue forecasts for Wegovy and its diabetes therapy Ozempic.
In August 2022, the US Federal Drug Administration (FDA) allowed compounding pharmacies, together with these working with telehealth suppliers like Hims & Hers, to repeat and distribute semaglutide weight-loss and weight-management medicine as a consequence of shortages in brand-name merchandise like Wegovy and Eli Lilly’s (LLY) Zepbound after huge shopper demand.
The transfer allowed Hims & Hers to market a GLP-1 weight-loss drug itself whereas the scarcity was in place, which it started doing in Could 2024, based on the Monetary Instances. However the FDA ended that order in February, citing that the scarcity of brand-name GLP-1s had ended and ordering compounding pharmacies to cease manufacturing by April.
Coming off the FDA ruling, Hims & Hers is attempting to diversify its product choices. Administration introduced in Could in a Q1 shareholder letter that its “imaginative and prescient includes increasing from lots of of personalised therapies right now to doubtlessly hundreds.”
Nonetheless, the corporate’s inventory has been a giant winner this yr relative to GLP-1 leaders like Novo Nordisk and Eli Lilly, rising greater than 150% yr so far in opposition to a greater than 40% slide for Novo Nordisk shares. Eli Lilly inventory is roughly flat this yr.
“The momentum we noticed by means of the primary half of 2025 is proof that our platform is delivering precisely what hundreds of thousands of individuals have been ready for, entry to personalised, high-quality care that meets folks the place they’re,” CEO Andrew Dudum mentioned throughout the Hims & Hers Q2 earnings name.
